EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Selective TRPV2 Antagonists Derived from the Natural Product Piperlongumine Inhibit Cancer Cell Migration and Metastasis

Hannah Kiely-Collins, Cong Tang iD, Marta C Marques, Laura Butron, Angela Lamberti iD, Nicholas Bossons, Fabian Offensperger iD, Vincenth Brennsteiner, Bárbara Sousa, Luís Carvalho, Antonio Ferrer-Montiel, Francisco Corzana iD and 3 more

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.5c00935 ↗

At a glance

Journal article in ACS Chemical Biology, 2026. Written by Hannah Kiely-Collins and 14 co-authors. Institution: Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K. Major MEDLINE topics: TRPV Cation Channels, Dioxolanes, Cell Movement, Biological Products. Cited 2 times so far (Crossref); 85 references. The full text is freely available (open access, CC BY 4.0). Funded by: Generalitat Valenciana, Agencia Estatal de Investigaci?n, European Regional Development Fund.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

TRPV2 is the least studied member of the vanilloid TRP subfamily despite its emerging relevance in cancer metastasis, pain, and inflammation. Although several small-molecule TRPV2 modulators have been reported, including the natural products piperlongumine (PL) and cannabidiol, all lack selectivity, complicating the interpretation of phenotypic readouts and functional insights into the role of the channel in health and disease. Here, we report a series of PL-based derivatives rationally designed to maintain TRPV2 antagonism while eliminating covalent off-target activity associated with the electrophilic groups present in PL. Using electrophysiological and calcium fluorescence imaging assays in HEK293T cells and DRG nociceptors, we identified HKC54 as the most potent TRPV2 antagonist to date (IC50 = 0.4 μM), displaying ∼50-fold selectivity over TRPV1 and ∼70-fold selectivity over TRPA1. Cellular thermal shift assays demonstrated direct TRPV2 engagement, and molecular dynamics and docking studies suggest a near-identical binding mode of the derivatives to PL. To assess proteome-wide selectivity, we pursued an unbiased chemoproteomic strategy and developed photoaffinity probes derived from PL and noncovalent derivative HKC22. Whereas the PL-based probe labeled many established covalent and noncovalent PL targets (e.g., GSTP1, GSTO1, STAT3, and KEAP1), no off-targets were detected for HKC22, suggesting high selectivity for TRPV2. Finally, PL derivatives inhibited cancer cell migration in vitro and suppressed metastasis in vivo, underscoring the therapeutic potential of selective TRPV2 antagonists.

Subjects

MeSH terms (MEDLINE)

TRPV Cation ChannelsDioxolanesCell MovementBiological ProductsAntineoplastic AgentsHumansHEK293 CellsPiperidonesNeoplasm MetastasisAnimalsCell Line, Tumor

Substances

TRPV Cation ChannelsDioxolanespiperlonguminePiperidonesTRPV2 protein, humanBiological ProductsAntineoplastic Agents

Authors and institutions

  • Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K.
  • GIMM - Gulbenkian Institute for Molecular Medicine, Avenida Prof. Egas Moniz, Lisboa 1649-028, Portugal.
  • Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernandez, Avda. Universidad s/n, Elche 03202, Spain.
  • Chemprecise Lda, Torres Vedras 2560-247, Portugal.
  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-003, Portugal.
  • CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna 1090, Austria.

ORCID profiles: Cong Tang, Angela Lamberti, Fabian Offensperger, Francisco Corzana, Georg E Winter, Gonçalo J L Bernardes

Funding

  • Generalitat Valenciana
  • Agencia Estatal de Investigaci?n
  • European Regional Development Fund
  • H2020 Marie Sklodowska-Curie Actions
  • Biotechnology and Biological Sciences Research Council
  • Funda??o para a Ci?ncia e a Tecnologia
  • Universidad de La Rioja

Cite

APA

Kiely-Collins, H., Tang, C., Marques, M. C., Butron, L., Lamberti, A., Bossons, N., Offensperger, F., Brennsteiner, V., Sousa, B., Carvalho, L., Ferrer-Montiel, A., Corzana, F., Winter, G. E., Fernandez-Carvajal, A., & Bernardes, G. J. L. (2026). Selective TRPV2 Antagonists Derived from the Natural Product Piperlongumine Inhibit Cancer Cell Migration and Metastasis. ACS Chemical Biology. https://doi.org/10.1021/acschembio.5c00935

Vancouver

Kiely-Collins H, Tang C, Marques MC, Butron L, Lamberti A, Bossons N, et al. Selective TRPV2 Antagonists Derived from the Natural Product Piperlongumine Inhibit Cancer Cell Migration and Metastasis. ACS Chemical Biology. 2026. doi:10.1021/acschembio.5c00935

BibTeX
@article{KielyCollins2026,
  author = {Kiely-Collins, Hannah and Tang, Cong and Marques, Marta C and Butron, Laura and Lamberti, Angela and Bossons, Nicholas and Offensperger, Fabian and Brennsteiner, Vincenth and Sousa, Bárbara and Carvalho, Luís and Ferrer-Montiel, Antonio and Corzana, Francisco and Winter, Georg E and Fernandez-Carvajal, Asia and Bernardes, Gonçalo J L},
  title = {Selective TRPV2 Antagonists Derived from the Natural Product Piperlongumine Inhibit Cancer Cell Migration and Metastasis},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.5c00935}
}
Start for free →